Observational studyInternational ophthalmology2025
Early success and safety of three minimally invasive glaucoma surgery techniques combined with cataract surgery in glaucoma patients.
Observational study in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy and safety of three minimally invasive glaucoma surgery (MIGS) techniques, OMNI® Surgical System (OMNI), VISCO360® Surgical System (VISCO) and goniotomy using the Kahook Dual Blade (KDB) in combination with phacoemulsification in glaucoma patients.
methodsThis prospective observational study over 6 months included 93 glaucoma patients who underwent one of the three MIGS combined with cataract surgery. Indications for surgery were insufficient intraocular pressure (IOP) control under topical medication or reducing the medication burden. Complete success was defined as reaching IOP < 21 mmHg without topical medication while qualified success was considered reaching IOP < 21 mmHg with topical medication.
resultsThe preoperative IOP was lowered significantly after 6 months for all 3 MIGS procedures and no significant differences in-between the 3 devices were recorded. Topical glaucoma medication was also reduced in all three groups, without a significant difference. Complete surgical success was the highest in KDB patients after 6 months at 74.2%, followed by 58.1% in VISCO and 48.4% in OMNI patients.
conclusionOMNI, VISCO or KDB in combination with phacoemulsification are safe and effective treatment options for glaucoma patients. The KDB and VISCO groups achieved higher success rates than OMNI, however, no significant differences in medication burden as well as IOP were recorded in-between the 3 devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.